{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:50:12Z","timestamp":1776487812216,"version":"3.51.2"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clcc.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T13:34:45Z","timestamp":1524317685000},"page":"e531-e539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine\/Tipiracil and Regorafenib"],"prefix":"10.1016","volume":"17","author":[{"given":"Anuj K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-1527","authenticated-orcid":false,"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihran A.","family":"Yenikomshian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy","family":"Wynant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Tabesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.04.002_bib1","author":"National Cancer Institute"},{"key":"10.1016\/j.clcc.2018.04.002_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.04.002_bib3","series-title":"Cancer Facts & Figures\u00a02017","author":"American Cancer Society","year":"2017"},{"key":"10.1016\/j.clcc.2018.04.002_bib4","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.04.002_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clcc.2018.04.002_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clcc.2018.04.002_bib7","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clcc.2018.04.002_bib8","first-page":"227","article-title":"Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer","volume":"22","author":"Seal","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clcc.2018.04.002_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.04.002_bib10","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.04.002_bib11","series-title":"Stivarga (regorafenib) Prescribing Information","year":"2012"},{"key":"10.1016\/j.clcc.2018.04.002_bib12","series-title":"Lonsurf (trifluridine and tipiracil) Prescribing Information","year":"2015"},{"key":"10.1016\/j.clcc.2018.04.002_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.04.002_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.04.002_bib15","first-page":"e15","article-title":"Regorafenib versus trifluridine\/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison","volume":"16","author":"Masuishi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.04.002_bib16","author":"US Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"10.1016\/j.clcc.2018.04.002_bib17","first-page":"756","article-title":"Methodological considerations in estimating adherence and persistence for a long-acting injectable medication","volume":"20","author":"Campagna","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clcc.2018.04.002_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1185\/03007995.2013.766164","article-title":"Revisiting the medication possession ratio threshold for adherence in lipid management","volume":"29","author":"Watanabe","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clcc.2018.04.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2018.04.002_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000448717","article-title":"Self-reported adherence to trifluridine and tipiracil hydrochloride for metastatic colorectal cancer: a retrospective cohort study","volume":"91","author":"Sugita","year":"2016","journal-title":"Oncology"},{"issue":"suppl 4S","key":"10.1016\/j.clcc.2018.04.002_bib21","article-title":"Self-reported adherence to regorafenib for metastatic colorectal cancer: a retrospective cohort study","volume":"35","author":"Kawakami","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clcc.2018.04.002_bib22","article-title":"Adherence to regorafenib therapy in patients with previously treated metastatic colorectal cancer: STI observational multicenter study","volume":"33","author":"Del Prete","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.04.002_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/fon-2016-0421","article-title":"Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study","volume":"13","author":"Del Prete","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.clcc.2018.04.002_bib24","first-page":"236","article-title":"Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib","volume":"23","author":"Chen","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clcc.2018.04.002_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0260-4","article-title":"A\u00a0practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry","volume":"33","author":"Blommestein","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clcc.2018.04.002_bib26","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.clcc.2018.04.002_bib27","author":"National Institute for Health and Care Excellence"},{"issue":"suppl 7","key":"10.1016\/j.clcc.2018.04.002_bib28","doi-asserted-by":"crossref","first-page":"vii100","DOI":"10.1093\/annonc\/mdv471.86","article-title":"Self-reported adherence with TAS-102","volume":"26","author":"Sugita","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.04.002_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy","year":"2015","journal-title":"Ther Adv Gastroenterol"},{"issue":"suppl 3","key":"10.1016\/j.clcc.2018.04.002_bib30","article-title":"MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer","volume":"32","author":"Bugano","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.04.002_bib31","first-page":"17","article-title":"Utility and pitfalls in the use of administrative databases for outcomes assessment","volume":"190","author":"Johnson","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clcc.2018.04.002_bib32","author":"US Food and Drug Administration Center for Drug Evaluation and Research"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818300094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818300094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:20Z","timestamp":1761519980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818300094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1533002818300094"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.04.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine\/Tipiracil and Regorafenib","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}